Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer

ABSTRACT: This is a trial investigating the efficacy and safety of Toripalimab combined with bevacizumab and chemotherapy as neoadjuvant therapy in patients with advanced microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR) colorectal cancer.

DISEASE(S): Colorectal Carcinoma,Colorectal Neoplasms

PROVIDER: 2385325 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR